文献速递骨质疏松与钙磷/甲状旁腺

长期地舒单抗对绝经后骨质疏松女性骨组织形态计量学与矿化的影响

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

国际多中心随机双盲FREEDOM试验及其开放标签延长研究,纳入提供髂骨活检的绝经后骨质疏松女性(FREEDOM 92例,延长研究46例),评估长达10年地舒单抗对骨组织学、重塑及基质矿化的影响。10年地舒单抗活检显示组织学正常、骨结构正常且骨重塑降低,与2/3年和5年时水平相似;与安慰剂相比,地舒单抗2/3年组骨矿化程度增加、矿化异质性降低;这些矿化变量从2/3年到5年有进展,之后无进一步变化。

要点

  • 地舒单抗治疗2/3年、5年和10年骨组织学正常,骨重塑率低。
  • 与安慰剂相比,地舒单抗2/3年组骨矿化程度增加、矿化异质性降低。
  • 矿化变量从2/3年到5年有进展,5年至10年无变化。

核心结论

  • 地舒单抗治疗2/3年、5年和10年与组织学正常、低骨重塑率、基质矿化增加和矿化异质性降低相关,这些变量从第5年到第10年无变化。
  • 这些数据结合先前报道的地舒单抗治疗长达10年骨折率维持低水平,提示强烈而持久的重塑抑制不损害骨强度。

研究设计与样本

  • 国际、多中心、随机、双盲试验FREEDOM(每6个月评估地舒单抗治疗骨质疏松骨折减少)及其长期开放标签延长研究。
  • 纳入提供髂骨活检的绝经后骨质疏松女性:FREEDOM 92例,延长研究46例,其中11例在多个时间点提供活检。
  • FREEDOM受试者按1:1随机接受皮下地舒单抗60 mg或安慰剂每6个月一次,持续3年;延长研究受试者继续开放标签接受地舒单抗7年。

主要发现

  • 10年地舒单抗活检显示组织学正常。
  • 骨组织形态计量学显示10年地舒单抗后骨结构正常且骨重塑降低,与地舒单抗2年或3年和5年后的水平相似。
  • 与安慰剂相比,地舒单抗2/3年组骨矿化程度增加、矿化异质性降低。
  • 这些矿化变量的变化从地舒单抗2/3年进展到5年,但之后无进一步进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Denosumab is a potent antiresorptive agent that reduces fractures in postmenopausal women with osteoporosis. OBJECTIVE: Determine effects of up to 10 years of denosumab on bone histology, remodeling, and matrix mineralization characteristics. DESIGN AND SETTING: International, multicenter, randomized, double-blind trial [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM)] with a long-term open-label extension. PATIENTS: Postmenopausal women with osteoporosis (92 women in FREEDOM, 46 in extension) who provided iliac bone biopsies, including 11 who provided biopsies at multiple time points. INTERVENTIONS: FREEDOM subjects were randomized 1:1 to subcutaneous denosumab 60 mg or placebo every 6 months for 3 years. Long-term extension subjects continued receiving denosumab, open-label, for 7 additional years. OUTCOMES: Bone histology, histomorphometry, matrix mineralization. RESULTS: Ten-year denosumab biopsies showed normal histology. Bone histomorphometry indicated normal bone structure and reduced bone remodeling after 10 years of denosumab, similar to levels after 2 and/or 3 and 5 years of denosumab. The degree of mineralization of bone was increased and mineralization heterogeneity was reduced in the denosumab years 2/3 group vs placebo. Changes in these mineralization variables progressed from years 2/3 to year 5 of denosumab, but not thereafter. CONCLUSIONS: Denosumab for 2/3, 5, and 10 years was associated with normal histology, low bone remodeling rate, increased matrix mineralization, and lower mineralization heterogeneity compared with placebo. These variables were unchanged from year 5 to year 10. These data, in combination with the maintenance of low fracture rates for up to 10 years as previously reported with denosumab therapy, suggest that strong, prolonged remodeling inhibition does not impair bone strength.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dempster DW, Brown JP, Fahrleitner-Pammer A, et al. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018. PMID: 29672714. doi:10.1210/jc.2017-02669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。